Skip to main content
. 2024 Apr 25;24:145. doi: 10.1186/s12876-024-03232-9

Table 1.

Baseline characteristics of patients grouped by sarcopenia

Parameters All Patients Sarcopenia No-sarcopenia p-value
(N) = available cases if values are missing % (total number) or median/mean (range/SD)
Number of patients 95 62.1% (59) 37.9% (36)
Sex 0.310
 Male 67.4% (64) 71.2% (42) 61.1% (22)
 Female 32.6% (31) 28.8% (17) 38.9% (14)
Age (median, range, in years) 45 (18–76) 46 (18–76) 41 (23–64) 0.369
BMI 25.7 (7.7) 24.8 (8.1) 27.1 (6.9) 0.167
PSC-IBD 70.5% (67) 66.1% (39) 77.8% (28) 0.226
Liver cirrhosis 51.6% (48) 61.0% (36) 33.3% (12) 0.017
LTX 35.8% (34) 47.5% (28) 16.7% (6) 0.002
Death 11.6% (11) 18.6% (11) 0% (0) 0.006
LTX/death (primary endpoint) 47.4% (45) 66.1% (39) 16.7% (6) < 0.001
Malignancy 20.0% (19) 25.4% (15) 11.1% (4) 0.091
Dominant stenosis 67.4% (64) 69.5% (41) 61.9% (23) 0.572
Ascites 40.0% (38) 54.2% (32) 16.7% (6) < 0.001
Hepatic Encephalopathy 13.7% (13) 16.9% (10) 8.3% (3) 0.236
Splenomegaly 48.4% (46) 57.6% (34) 33.3% (12) 0.022
BMI reduction > 10% in 12 months 16.8% (16) 22.0% (13) 8.3% (3) 0.083
Recurring cholangitis (≥ 2x/6 months) 16.8% (16) 22.0% (13) 8.3% (3) 0.083
SEG 27.4% (26) 37.3% (22) 11.1% (4) 0.006
MELD score (n = 94) 13.1 (8.2) 14.9 (8.7) 9.9 (6.2) 0.002
Child-Pugh Grade (n = 48) 0.001
 A 25.0% (12) 13.9% (5) 58.3% (7)
 B 50.0% (24) 55.6% (20) 33.3% (4)
 C 25.0% (12) 30.6% (11) 08.3% (1)
Mayo risk score (n = 67) 1.70 (1.87) 2.27 (1.81) 0.62 (1.52) <0.001
EASL 2022 CPG risk stratification < 0.001
 Low risk 22.1% (21) 15.3% (9) 33.3% (12)
 Significant risk 77.9% (74) 84.7% (50) 66.7% (24)
Platelets (103cells/µl) 227 (149) 231 (169) 219 (110) 0.708
Albumin (g/dl) (n = 67) 3.64 (0.86) 3.36 (0.86) 4.19 (0.57) < 0.001
Bilirubin (mg/dl) 5.0 (7.7) 6.5 (8.8) 2.7 (4.7) 0.019
INR (n = 90) 1.21 (0.41) 1.29 (0.45) 1.07 (0.32) 0.012
Creatinine (mg/dl) 0.9 (0.5) 0.9 (0.5) 0.9 (0.6) 0.855
Sodium (mmol/l) (n = 90) 138 (4) 137 (5) 140 (2) < 0.001
Mode of cross-sectional imaging 0.070
 CT 58.9% (56) 66.1% (39) 47.2% (17)
 MRI 41.1% (39) 33.9% (20) 52.8% (19)
Time interval between diagnosis of PSC and date of last imaging (years) 8.89 (7.52) 8.95 (7.71) 8.81 (7.32) 0.929
Loss to follow-up 23.2% (22) 15.3% (9) 36.1% (13) 0.019
Time of follow-up (years) 1.35 (2.06) 1.06 (1.66) 1.82 (2.53) 0.078
SMI (cm²/m²) 42.08(9.35) 37.55 (7.63) 49.49 (6.31) < 0.001

Abbreviations: BMI, body mass index; CT, computed tomography; EASL 2022 CPG, European Association for the Study of the Liver 2022 Clinical Practice Guidelines; INR, international normalized ratio; LTX, liver transplantation; MELD, Model of End-Stage Liver Disease; MRI, magnetic resonance imaging; PSC-IBD, patient with primary sclerosing cholangitis and associated inflammatory bowel disease: SEG, Standard Exception criteria of Germany; SMI, skeletal muscle index

HHS Vulnerability Disclosure